Flu Vaccines Hitting U.S. Shelves Soon

Flu Vaccines Hitting U.S. Shelves Soon
Flu Vaccines Hitting U.S. Shelves Soon

Novartis announced that it has begun shipment of its seasonal influenza vaccines for the 2014–2015 season, with a minimum shipment of 30 million doses of the Influenza Virus Vaccines, Flucelvax and Fluvirin prior to the influenza season peak.

Flucelvax (Influenza Virus Vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza subtypes A and B in adults ≥18 years of age. Fluvirin (Influenza Virus Vaccine) is an inactivated vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and B in people ≥4 years of age.

These vaccines contain antigens targeting three influenza virus strains identified by World Health Organization (WHO) experts as those most likely to dominate circulation this winter.

RELATED: Some RA Drugs May Reduce Vaccine Effectiveness

For Fluvirin, these include:

  • A/Christchurch/16/2010, NIB-74 (H1N1) (an A/California/7/2009-like virus)
  • A/Texas/50/2012, NYMC X-223A (H3N2) (an A/Victoria/361/2011-like virus)
  • B/Massachusetts/2/2012

For Flucelvax, these include:

  • A/Brisbane/10/2010 (H1N1) (an A/California/7/2009-like virus)
  • A/Texas/50/2012, NYMC X-223A (H3N2) (an A/Victoria/361/2011-like virus)
  • B/Massachusetts/2/2012

The vaccines can be obtained at pharmacy retailers, wholesalers, and distributors and will be available in formulations based on cell-culture (Flucelvax) and eggs (Fluvirin).

For more information call (800) 693-9993 or visit Novartis.com.

Loading links....